CORE-005: LEUKEMIA TISSUE BANK SHARED RESOURCE (LTB) PROJECT SUMMARY / ABSTRACT The OSUCCC Leukemia Tissue Bank (LTB) is a critical resource for OSUCCC investigators, and the Leukemia Research Program, conducting translational research in hematologic malignancies. The LTB procures samples in 2 ways, via a general biobanking protocol as well as using specific clinical research protocols, collecting blood, bone marrow, leukapheresis products and others as requested. The LTB performs rapid processing of biospecimens, e.g., cell isolation and cryopreservation, assesses the quality of collected samples, delivers fresh samples or stores them for future use, provides clinical annotation for study subjects and distributes samples to investigators. Additional services available to researchers include serial collections, specialized processing, specialized specimen preparation and characterization, protocol optimization, and assistance with design of laboratory and clinical correlative studies. The LTB is a longstanding biobank, and with a >90% subject participation rate, it has collected 14,233 samples from 5,195 subjects, allowing for detailed investigations of many subtypes of hematologic cancers. Dr. Lucas is the Director of the LTB, and Dr. Bloomfield is the Senior Faculty Advisor.
The Specific Aims of the LTB are: 1) to consent subjects and procure samples from hematologic malignancy patients using state-of-the art procedures to optimally preserve the value of patient materials; 2) to uniformly process, characterize and store biospecimens; and, 3) to provide biospecimens with associated clinical, pathological and genomic data to OSUCCC researchers and to outside institutions so that they can correlate findings from patient samples with clinical or population-based outcomes. The LTB coordinates with other OSUCCC shared resources, e.g., Analytical Cytometry, Genomics, Pharmacoanalytical, and the Clinical Trials Processing Laboratory. During the last five year grant period, the LTB supported the research of 34 investigators, 30 of whom were OSUCCC members. Together, the LTB samples were used for 98 publications, of which 18 were published in journals with an impact factor >10, and 15 NCI grants. As a future direction, the facility will be expanded with OSUCCC support as required to meet researchers' needs. Working with the Genomics Shared Resource and the Bioinformatics Shared Resource, we will embark upon indexing leukemia samples based on genomic profiles. The LTB leverages extensive institutional support and seeks only 15.3% support from CCSG funds. The Leukemia Tissue Bank Shared Resource is part of the Clinical Grouping.
|Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819|
|Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294|
|Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859|
|Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954|
|Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471|
|Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427|
|Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322|
|Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874|
|Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814|
|Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :|
Showing the most recent 10 out of 2211 publications